Technology Innovative technologies lead
to medical progress

Experience our Spectacular Science

At Regeneron, we don't shy away from a scientific challenge because we know nothing is out of bounds. We follow the science to find solutions to insurmountable problems in human health. We question everything. This philosophy is what inspires us to harmonize biology and technology, marrying the best of both to revolutionize research on how we target and treat serious diseases. It's why we created the Regeneron Genetics Center®, home to the largest and most diverse genomic database in the world. It's why we are perfecting novel technologies like CRISPR and gene silencing. And it's why we'll continue to stay on the cutting edge as we build the medicines of tomorrow.

Male scientist working in a lab.

Technology for now
and the future

Male scientist working in a lab.

Technology is foundational to our work inventing new medicines. By combining the deep scientific expertise of our team with our proprietary VelociSuite® technologies, as well as other complementary technologies, we accelerate the way medicines are traditionally discovered and developed. Building on our portfolio of homegrown medicines, we continue to evolve our approach to antibody discovery and development, while also exploring new methods of addressing human disease, like gene editing.

0ur VelociSuite® technology platform

Overview video of Regeneron's VelociSuite® technology platform.

Our industry-leading capabilities for antibody target discovery and validation are enabled by a series of Regeneron-invented technologies that accelerate, improve and disrupt the traditional process. VelociSuite includes some of the most valuable biotechnologies ever created and has enabled the development of approximately one in five of all original, FDA-approved or authorized fully human monoclonal antibodies currently on the market.

These tools ultimately allow us to help more patients around the world, faster. Regeneron also provides the VelociSuite technologies to its collaborators as vital services to assist in the drug discovery and development process.

VelociGene® video
VelociGene®

VelociGene facilitates the rapid, automated and high-scale manipulation of mouse DNA, with almost no limitations on the size and sophistication of these modifications. This enables unprecedented speed and capacity for the validation of therapeutic targets and the creation of animal models of human disease – critical first steps in process of developing new medicines.

VelocImmune® video
VelocImmune®

VelocImmune is our unique technology for producing optimized fully human monoclonal antibodies. It utilizes a proprietary mouse platform engineered with a genetically humanized immune system. VelocImmune creates a multitude of antibody drug candidates efficiently and directly from immunized mice, overcoming limitations of traditional platforms by rapidly creating fully human antibodies that tightly bind to therapeutic targets and avoid potential negative immune responses that may occur in patients receiving antibodies that contain nonhuman (typically mouse) components.

VelocImmune stems from Chief Scientific Officer George D. Yancopoulos’ work as a graduate student, when he was the first to envision making such a genetically humanized mouse.

VelociMab® video
VelociMab®

VelociMab is a group of technologies that allow us to move with unprecedented speed from identification of a therapeutic antibody into clinical studies. VelociMab enables the high-throughput screening of potential therapeutic antibodies and the rapid generation of cell lines for recombinant human antibodies. This allows us to select the best candidates and prepare them for initial manufacturing in record time – going from mouse immunization to production cell line bioreactor harvest within eight months.

VelociMouse®

VelociMouse is a breakthrough technology that enables the immediate generation of genetically altered mice directly from modified embryonic stem cells, thereby avoiding the need to breed multiple generations of mice. This technology has dramatically shortened the time needed to engineer genetically modified mice, while at the same time reducing costs and improving precision.

VelociT®

VelociT is our service for producing genetic sequences for our partners and collaborators to assist in the creation of fully human therapeutic T-cell receptors (TCR) against tumor and viral antigens.

VelociHum®

VelociHum is our immunodeficient mouse platform that can be used to accurately test human therapeutics against human immune cells and to study human tumor models. Through genetic humanizations, VelociHum mice have been optimized to allow for better development of human immune cells in vivo, as well as to allow for engraftment of primary patient-derived tumors that do not take in other commercially available mice.

Veloci-Bi®

Veloci-Bi allows for the generation of full-length bispecific antibodies similar to native antibodies that are amenable to being made through standard antibody manufacturing techniques and are likely to have favorable, antibody-like pharmacokinetic properties.

Advancing our technologies video.

Advancing our technologies

We continually push the bounds of science to discover new ways to make a positive impact on human health – and this also applies to our technologies. Just as we have continued to develop the VelociSuite platform over decades, like with the addition of Veloci-Bi, we are also pursuing other innovative ways to address diseases, including with genetic medicine approaches.

Close-up of DNA-based vaccine technology.

Case Study

Applying our tech to discover DNA-based vaccines

The Molecular Vaccine Technology Center was launched in 2021 to provide internal support to our researchers who are developing molecular vaccines for oncology, infectious disease and immune inflammation approaches. The Molecular Vaccine Tech Center will establish in-house plasmid DNA and mRNA vaccine platforms to deliver antigens either to dendritic cells or directly to T cells for activation.

Our teams can fast-track vaccine projects by screening hundreds of vaccine candidates in combination with different DNA, mRNA and protein delivery approaches in order to select leads for clinical investigation.

In addition, at the end of 2021, Regeneron entered into a multi-year collaboration agreement with Nykode Therapeutics (formerly Vaccibody) to develop innovative vaccines against cancer and infectious diseases. Nykode has developed a plasmid DNA-launched vaccine platform that efficiently delivers antigens to help kickstart an immune response. The protein product that is launched by the plasmid DNA, the so-called “Vaccibody,” contains a series of encoded antigens linked to a targeting domain that promotes delivery to dendritic cells, which initiate an immune response. The platform has already shown robust CD8 T-cell responses in animal models and in patients with cancer.

Female scientist working in a lab.

Case Study

Bispecific antibody clinical progress thanks to advancing technologies

To solve the human body’s most complex mysteries, we must continually build upon our existing technologies, just as we have done with Veloci-Bi. We developed the platform to overcome common issues seen with other bispecific creation methods, such as undesired immune responses or instability in vivo. By addressing these hurdles, we can create high quality bispecific antibodies at fast speeds.

As our bispecific antibody pipeline matures, we are encouraged by progress to address solid tumors and hematological conditions. Check out our clinical pipeline to see our bispecific antibody candidates.

Regeneron Trap technology

Regeneron’s deep scientific
expertise across modalities

Traps

Our Trap technology was motivated by a dissatisfaction with the specificity and binding affinity of human antibodies that could be developed using the most-advanced antibody technologies at the time. Building on insights into the basic mechanisms of receptor action discovered at Regeneron, our scientists developed a general approach to create high-affinity blockers for many different types of signaling molecules. This novel Regeneron Trap technology creates circulating "decoy receptors" capable of reducing or eliminating the harmful effects of a signaling protein.

Female scientist working in a lab.

Pipeline

Thanks to our innovative technologies and dedicated team, we have dozens of investigational medicines in the clinical pipeline across many diseases.

See what's in the pipeline

Expertise in cell production

Our EESYR®, FASTR® and NICE® technologies and services significantly increase protein-production yields in cell-line development for our research and clinical programs, as well as for our partners:

  • EESYR provides site-specific integration into a transcriptional hot spot in the eukaryotic cell genome, resulting in rapid isolation of cells capable of high-level expression of recombinant therapeutic proteins
  • FASTR is a quantitative cell-surface display technology that enables the use of flow cytometry to select eukaryotic cells that secrete the highest levels of recombinant therapeutic proteins
  • NICE enables the control of the expression of secreted, recombinant therapeutic proteins in eukaryotic cells
Rapid Response

Our rapid response to
infectious diseases

We are always looking for ways to make the drug discovery process faster and more efficient, especially when help is desperately needed in a short amount of time. To address emerging or rapidly spreading infectious diseases, Regeneron has applied our VelociSuite technologies in a ‘rapid response’ manner that parallel tracks certain steps and speeds hand-offs between groups in order to advance novel antibody treatments faster than ever. We’ve been proud to apply our homegrown technologies and novel scientific approach to respond to public health challenges like Ebola, Middle Eastern Respiratory Syndrome (MERS) and COVID-19.

HOW WE’RE WORKING TO IMPROVE LIVES

Back
to top